Preparation of fab-fragments of GD2-specific antibodies and analysis of their antitumor activity in vitro

Bulletin of Experimental Biology and Medicine

Volumn 154, Issue 5, 2013, Pages 658-663

  Doronin, I I ^a   Kholodenko, I V ^b   Molotkovskaya, I M ^a   Kholodenko, R V ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

Author keywords

apoptosis; Fab fragments; mice T lymphoma EL 4; monoclonal GD2 specific antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; GANGLIOSIDE GD2; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY ME361; PAPAIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOT HYBRIDIZATION; DRUG BINDING; DRUG ISOLATION; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; T CELL LYMPHOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; ASCITIC FLUID; CELL LINE, TUMOR; CELL PROLIFERATION; GANGLIOSIDES; HYBRIDOMAS; IMMUNOGLOBULIN FAB FRAGMENTS; LYMPHOMA, T-CELL; MICE;

MUS;

EID: 84878876468     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-013-2024-5     Document Type: Article

References (10)

1. V. V. Burunova, A. M. Gisina, I. V. Kholodenko, et al., Kletochn. Tekhnol. In Biol. Med., No. 2, 63-67 (2010).
2. A. A. Konieva, I. V. Kholodenko, O. A. Shragina, et al., Ibid., No. 3, 147-152 (2010).
3. I. V. Kholodenko, I. I. Doronin, and R. V. Kholodenko, Sovr. Probl. Dermatovenerol. Immunol. Vrachebn. Kosmetol., No. 5, 76-80 (2010).
4. R. V. Kholodenko, Ibid., No. 1, 17-23 (2010).
5. W. Aixinjueluo, K. Furukawa, Q. Zhang, et al., J. Biol. Chem., 280, No. 33, 29,828-29,836 (2005).
6. O.H. Brekke and I. Sandlie, Nat. Rev. Drug Disc., 2, No. 1, 52-62 (2003).
7. A. Kowalczyk, M. Gil, I. Horwacik, et al., Cancer Lett., 281, No. 2, 171-182 (2009).
8. F. Navid, M. Armstrong, and R. C. Barfield, Cancer Biol. Ther., 8, No. 10, 874-882 (2009).
9. L. Sanz, A. M. Cuesta, M. Compte, and L. Alvazez-Vallina, Acta. Pharmacol. Sin., 26, No. 6, 641-648 (2005).
10. W. G. Telford, A. Komoriya, and B. Z. Packard, Methods Mol. Biol., 263, 141-160 (2004).